Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Sykes

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Expert Opinion on Therapeutic Targets|October 16, 2018
The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemiaDavid B Sykes
The American Journal of Medicine|October 1, 2022
Auto-PhlebotomyDavid B Sykes
JAMA Oncology|September 13, 2019
Insights From a Patient With Lung Cancer-Party Therapy Is Way Better Than ChemotherapyDavid B Sykes
The New England Journal of Medicine|June 7, 2018
Complete Responses in the TEMPI Syndrome after Treatment with DaratumumabDavid B Sykes, Wilfried Schroyens
The New England Journal of Medicine|January 8, 2025
Teclistamab as Successful Treatment of Relapsed TEMPI SyndromeDavid B Sykes, Wilfried Schroyens
BMC Hematology|August 22, 2014
Case report: a 37-year-old male with telangiectasias, polycythemia vera, perinephric fluid collections, and intrapulmonary shuntingJaved Khan, David B Sykes
BMJ Case Reports|July 31, 2017
Acquired haemophilia A with a recalcitrant high-titre factor VIII inhibitor in the setting of interstitial lung diseaseLova Sun, David B Sykes
Journal of Graduate Medical Education|July 29, 2015
There Is No Denying It, Our Medical Language Needs an UpdateDavid B Sykes, Darren N Nichols
Leukemia & Lymphoma|August 15, 2003
Estrogen-regulated conditional oncoproteins: tools to address open questions in normal myeloid cell function, normal myeloid differentiation, and the genetic basis of differentiation arrest in myeloid leukemiaDavid B Sykes, Mark P Kamps
Molecular and Cellular Biology|January 20, 2004
E2a/Pbx1 induces the rapid proliferation of stem cell factor-dependent murine pro-T cells that cause acute T-lymphoid or myeloid leukemias in miceDavid B Sykes, Mark P Kamps
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Expert Opinion on Therapeutic Targets|October 16, 2018
The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemiaDavid B Sykes
The American Journal of Medicine|October 1, 2022
Auto-PhlebotomyDavid B Sykes
JAMA Oncology|September 13, 2019
Insights From a Patient With Lung Cancer-Party Therapy Is Way Better Than ChemotherapyDavid B Sykes
The New England Journal of Medicine|June 7, 2018
Complete Responses in the TEMPI Syndrome after Treatment with DaratumumabDavid B Sykes, Wilfried Schroyens
The New England Journal of Medicine|January 8, 2025
Teclistamab as Successful Treatment of Relapsed TEMPI SyndromeDavid B Sykes, Wilfried Schroyens
BMC Hematology|August 22, 2014
Case report: a 37-year-old male with telangiectasias, polycythemia vera, perinephric fluid collections, and intrapulmonary shuntingJaved Khan, David B Sykes
BMJ Case Reports|July 31, 2017
Acquired haemophilia A with a recalcitrant high-titre factor VIII inhibitor in the setting of interstitial lung diseaseLova Sun, David B Sykes
Journal of Graduate Medical Education|July 29, 2015
There Is No Denying It, Our Medical Language Needs an UpdateDavid B Sykes, Darren N Nichols
Leukemia & Lymphoma|August 15, 2003
Estrogen-regulated conditional oncoproteins: tools to address open questions in normal myeloid cell function, normal myeloid differentiation, and the genetic basis of differentiation arrest in myeloid leukemiaDavid B Sykes, Mark P Kamps
Molecular and Cellular Biology|January 20, 2004
E2a/Pbx1 induces the rapid proliferation of stem cell factor-dependent murine pro-T cells that cause acute T-lymphoid or myeloid leukemias in miceDavid B Sykes, Mark P Kamps
Pageof 13